≡

Cytochrome P450 2C18 (CYP2C18)

[Edit]

CYP2C; CPCI; CYP2C17; CPCJ; P450C2C; limonene 6-monooxygenase; Mephenytoin 4-hydroxylase; Cytochrome P450 Family 2 Subfamily C Polypeptide 18

Cytochrome P450 2C18 (CYP2C18)
CCC D301
HGNC 2620
PubMed 15301741
RGD 2469
UniProt P33260
Wiki CYP2C18
Cytochrome P450 2C18 isa member of the cytochrome P450 superfamily of enzymes. This protein localizes to the endoplasmic reticulum but its specific substrate has not yet been determined. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24. An additional gene, CYP2C17, was once thought to exist; however, CYP4217 is now considered an artefact based on a chimera of CYP2C18 and CYP2C19.
Cytochrome P450 2C19, a member of the cytochrome P450 mixed-function oxidase system, is involved in the metabolism of xenobiotics in the body.It is involved in the metabolism of several important groups of drugs including many proton pump inhibitors and antiepileptics.

Organism species: Homo sapiens (Human)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Recombinant Cytochrome P450 2C18 (CYP2C18) Recombinant Protein Customized Service Offer
Antibodies n/a Monoclonal Antibody to Cytochrome P450 2C18 (CYP2C18) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Cytochrome P450 2C18 (CYP2C18) Polyclonal Antibody Customized Service Offer
Assay Kits SED301Hu ELISA Kit for Cytochrome P450 2C18 (CYP2C18) Enzyme-linked immunosorbent assay for Antigen Detection.

Organism species: Rattus norvegicus (Rat)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Recombinant Cytochrome P450 2C18 (CYP2C18) Recombinant Protein Customized Service Offer
Antibodies n/a Monoclonal Antibody to Cytochrome P450 2C18 (CYP2C18) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Cytochrome P450 2C18 (CYP2C18) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Cytochrome P450 2C18 (CYP2C18) CLIA Kit Customized Service Offer
n/a ELISA Kit for Cytochrome P450 2C18 (CYP2C18) ELISA Kit Customized Service Offer
  1. "Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily."Biochemistry 30:3247-3255(1991) [PubMed] [Europe PMC] [Abstract]
  2. ErratumBiochemistry 32:1390-1390(1993) [PubMed] [Europe PMC] [Abstract]
  3. "The DNA sequence and comparative analysis of human chromosome 10." Nature 429:375-381(2004) [PubMed] [Europe PMC] [Abstract]
  4. "Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation."Arch. Biochem. Biophys. 306:240-245(1993) [PubMed] [Europe PMC] [Abstract]
  5. "Metabolism of (+)- and (-)-limonenes to respective carveols and perillyl alcohols by CYP2C9 and CYP2C19 in human liver microsomes."Drug Metab. Dispos. 30:602-607(2002) [PubMed] [Europe PMC] [Abstract]
  6. "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome."J. Proteomics 96:253-262(2014) [PubMed] [Europe PMC] [Abstract]
  7. "Structural characterization of human cytochrome P450 2C19: active site differences between P450s 2C8, 2C9, and 2C19."J. Biol. Chem. 287:44581-44591(2012) [PubMed] [Europe PMC] [Abstract]
  8. "The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans."J. Biol. Chem. 269:15419-15422(1994) [PubMed] [Europe PMC] [Abstract]
  9. "Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese."Mol. Pharmacol. 46:594-598(1994) [PubMed] [Europe PMC] [Abstract]
  10. "Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele."J. Pharmacol. Exp. Ther. 281:604-609(1997) [PubMed] [Europe PMC] [Abstract]
  11. "Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin."J. Pharmacol. Exp. Ther. 286:1490-1495(1998) [PubMed] [Europe PMC] [Abstract]
  12. "An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians."Pharmacogenetics 8:129-135(1998) [PubMed] [Europe PMC] [Abstract]
  13. "A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin."J. Pharmacol. Exp. Ther. 290:635-640(1999) [PubMed] [Europe PMC] [Abstract]
  14. "Identification and functional characterization of new potentially defective alleles of human CYP2C19."Pharmacogenetics 12:703-711(2002) [PubMed] [Europe PMC] [Abstract]
  15. "A novel single nucleotide polymorphism (SNP) of the CYP2C19 gene in a Japanese subject with lowered capacity of mephobarbital 4'-hydroxylation."Drug Metab. Pharmacokinet. 19:236-238(2004) [PubMed] [Europe PMC] [Abstract]
  16. "Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population."Pharmacogenomics 5:895-931(2004) [PubMed] [Europe PMC] [Abstract]
  17. "Genetic variations and haplotypes of CYP2C19 in a Japanese population."Drug Metab. Pharmacokinet. 20:300-307(2005) [PubMed] [Europe PMC] [Abstract]